Japan’s PMDA Clarifies Requirements for Companion Diagnostic PMAs

International Medical Device Regulatory Monitor
A A
Companies filing premarket approval applications for companion diagnostics may explain the clinical significance and clinical cut-off of their products using a summary of the clinical results for the corresponding drug product, recent technical guidance from Japan’s Pharmaceuticals and Medical Devices Agency says.

To View This Article:

Login

Subscribe To International Medical Device Regulatory Monitor

Buy This Article Now

Add this article to your cart for $40.00